AU2006279218B2 - Reducing post-operative adhesion formation with intraperitoneal glutamine - Google Patents

Reducing post-operative adhesion formation with intraperitoneal glutamine Download PDF

Info

Publication number
AU2006279218B2
AU2006279218B2 AU2006279218A AU2006279218A AU2006279218B2 AU 2006279218 B2 AU2006279218 B2 AU 2006279218B2 AU 2006279218 A AU2006279218 A AU 2006279218A AU 2006279218 A AU2006279218 A AU 2006279218A AU 2006279218 B2 AU2006279218 B2 AU 2006279218B2
Authority
AU
Australia
Prior art keywords
glutamine
composition
source
adhesion formation
alanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006279218A
Other languages
English (en)
Other versions
AU2006279218A1 (en
Inventor
Adebola O.E. Obayan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADETHERAPEUTICS Inc
Original Assignee
ADETHERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADETHERAPEUTICS Inc filed Critical ADETHERAPEUTICS Inc
Publication of AU2006279218A1 publication Critical patent/AU2006279218A1/en
Priority to AU2013204912A priority Critical patent/AU2013204912B2/en
Priority to AU2013204918A priority patent/AU2013204918A1/en
Application granted granted Critical
Publication of AU2006279218B2 publication Critical patent/AU2006279218B2/en
Assigned to ADETHERAPEUTICS, INC. reassignment ADETHERAPEUTICS, INC. Request for Assignment Assignors: UNIVERSITY OF SASKATCHEWAN
Priority to AU2016266102A priority patent/AU2016266102B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2006279218A 2005-08-11 2006-08-11 Reducing post-operative adhesion formation with intraperitoneal glutamine Active AU2006279218B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2013204912A AU2013204912B2 (en) 2005-08-11 2013-04-12 Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2013204918A AU2013204918A1 (en) 2005-08-11 2013-04-12 Reducing post-operative adhesion formation with intrapertoneal glutamine
AU2016266102A AU2016266102B2 (en) 2005-08-11 2016-12-02 Reducing post-operative adhesion formation with intraperitoneal glutamine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70717305P 2005-08-11 2005-08-11
US60/707,173 2005-08-11
PCT/CA2006/001319 WO2007016791A1 (en) 2005-08-11 2006-08-11 Reducing post-operative adhesion formation with intraperitoneal glutamine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2013204912A Division AU2013204912B2 (en) 2005-08-11 2013-04-12 Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2013204918A Division AU2013204918A1 (en) 2005-08-11 2013-04-12 Reducing post-operative adhesion formation with intrapertoneal glutamine

Publications (2)

Publication Number Publication Date
AU2006279218A1 AU2006279218A1 (en) 2007-02-15
AU2006279218B2 true AU2006279218B2 (en) 2013-05-02

Family

ID=37727066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006279218A Active AU2006279218B2 (en) 2005-08-11 2006-08-11 Reducing post-operative adhesion formation with intraperitoneal glutamine

Country Status (14)

Country Link
US (5) US20100260819A1 (https=)
EP (1) EP1940439B1 (https=)
JP (1) JP5194207B2 (https=)
AT (1) ATE485829T1 (https=)
AU (1) AU2006279218B2 (https=)
CA (1) CA2618600C (https=)
CY (1) CY1112051T1 (https=)
DE (1) DE602006017864D1 (https=)
DK (1) DK1940439T3 (https=)
ES (1) ES2355159T3 (https=)
PL (1) PL1940439T3 (https=)
PT (1) PT1940439E (https=)
SI (1) SI1940439T1 (https=)
WO (1) WO2007016791A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1940439E (pt) 2005-08-11 2010-12-17 Univ Saskatchewan Redução da formação de aderências pós-operatórias com glutamina intraperitoneal
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
JP5433424B2 (ja) 2007-03-02 2014-03-05 シュトプロテック ゲーエムベーハー グルタミン残基を含む炭水化物系腹膜透析液
US20100082113A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
RU2578426C2 (ru) * 2010-06-28 2016-03-27 Эдитерапьютикс, Инк. Лечение келоидов
WO2014027545A1 (ja) 2012-08-16 2014-02-20 ニプロ株式会社 癒着防止材
WO2017190148A1 (en) * 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
EP3471791B1 (en) 2016-06-15 2020-08-05 Tubitak Multifunctional hernia patch
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
WO2022234489A1 (en) 2021-05-07 2022-11-10 Temple Therapeutics BV Methods of treating fibrosis and hypoxia-associated damage to peripheral nerves
WO2025163204A1 (en) 2024-02-01 2025-08-07 Temple Therapeutics BV Glutamine source for use in methods and compositions for reducing or preventing synovial joint adhesions or fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501540A1 (en) * 2002-10-08 2004-04-22 Abbott Laboratories Methods and compositions for providing glutamine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026881A1 (en) * 1989-02-08 1990-08-09 Masao Tanihara Peptide and adsorbent thereof immobilized on carrier
US5248697A (en) 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
CA2114290C (en) * 1993-01-27 2006-01-10 Nagabushanam Totakura Post-surgical anti-adhesion device
US5425740A (en) * 1994-05-17 1995-06-20 Hutchinson, Jr.; William B. Endoscopic hernia repair clip and method
US6965014B1 (en) * 1996-01-16 2005-11-15 Baxter International Inc. Fibrin material and method for producing and using the same
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
GB9609993D0 (en) 1996-05-14 1996-07-17 Norbrook Lab Ltd Oral rehydration product
US6797729B1 (en) * 1996-06-28 2004-09-28 Baxter International Inc. Therapeutic glutamine and N-actyl-cysteine composition
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
CA2330939A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
US6613070B2 (en) * 1998-08-04 2003-09-02 Baxter International Inc. System and method for sealing vascular penetrations with hemostatic gels
US20030007951A1 (en) 2000-08-23 2003-01-09 Richard Franklin Treatment of trauma
CA2538680A1 (en) 2003-09-26 2005-04-07 Bristol-Myers Squibb Company Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
PT1940439E (pt) * 2005-08-11 2010-12-17 Univ Saskatchewan Redução da formação de aderências pós-operatórias com glutamina intraperitoneal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501540A1 (en) * 2002-10-08 2004-04-22 Abbott Laboratories Methods and compositions for providing glutamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DORUK, N. et al., J. Parenter. Enteral Nutr. (2005), vol. 29(1), pp. 36-43* *
FUENTES-OROZCO C. et al., Clinical Nutrition (2004), vol. 23, no. 1, pages 13-21 *

Also Published As

Publication number Publication date
US20100260819A1 (en) 2010-10-14
PL1940439T3 (pl) 2011-04-29
US20130171209A1 (en) 2013-07-04
WO2007016791A1 (en) 2007-02-15
EP1940439B1 (en) 2010-10-27
ATE485829T1 (de) 2010-11-15
SI1940439T1 (sl) 2011-02-28
CY1112051T1 (el) 2015-11-04
JP5194207B2 (ja) 2013-05-08
EP1940439A1 (en) 2008-07-09
DE602006017864D1 (de) 2010-12-09
CA2618600A1 (en) 2007-02-15
US20150250928A1 (en) 2015-09-10
EP1940439A4 (en) 2009-07-08
PT1940439E (pt) 2010-12-17
US20190111189A1 (en) 2019-04-18
US10799622B2 (en) 2020-10-13
WO2007016791A8 (en) 2008-09-18
DK1940439T3 (da) 2011-02-14
AU2006279218A1 (en) 2007-02-15
HK1120223A1 (en) 2009-03-27
CA2618600C (en) 2017-05-02
ES2355159T3 (es) 2011-03-23
JP2009504576A (ja) 2009-02-05
US9011883B2 (en) 2015-04-21
US20170203013A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US10799622B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
EP0590015B1 (en) Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US6440427B1 (en) Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
CN103002903B (zh) 瘢痕疙瘩治疗法
US20100105628A1 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2016266102B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2013204912B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
HK1120223B (en) Reducing post-operative adhesion formation with intraperitoneal glutamine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 60/707,173 11 AUG 2005 US

PC1 Assignment before grant (sect. 113)

Owner name: ADETHERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SASKATCHEWAN

FGA Letters patent sealed or granted (standard patent)